Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.
about
Autoantibodies in cryptogenic fibrosing alveolitisPrivate specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitisIdentification of novel autoantibodies for detection of malignant mesotheliomaPHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients.Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.What's the place of immunotherapy in malignant mesothelioma treatments?Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Auto-antibodies to β-F1-ATPase and vimentin in malignant mesotheliomaGenetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.The Role of Regulatory T Cells in Mesothelioma.Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer.p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma.CD40-activated B cells contribute to mesothelioma tumor regression.
P2860
Q24791773-798EC6C3-1D54-4730-82C5-FAA6E7171E7EQ24804539-AEBDF4EA-57CA-4F7D-B2F1-F963C24E4138Q28387447-F0630621-AEAB-4EE1-B870-4E52F1D7C4B2Q30690737-94A65898-A5A4-45BB-8AE0-8FD1CC766978Q30958980-80D796A1-1337-4A88-9136-68F381CF48AAQ33443439-F1A204A1-FB4F-42C1-B0BF-425A90A7EF76Q33781142-BA83D415-CB20-4762-98B8-FD3B1B1F440BQ33871059-4F4BE5E0-C5EF-433A-8589-2E6238888BECQ34056345-9D52293B-5840-40FA-BE77-8B79FCDCB2F3Q35699080-1F0F8FDC-A17E-435F-8A73-C0D7B4BB4C35Q36101238-C9837BC6-20E4-475E-BD1A-02E74C192174Q36510112-A3ADC24B-72B9-4DC8-B29F-860BFF1A58F7Q36622181-44291889-F59E-40AC-A22E-243F1B23D48BQ36871710-DA6F0261-A2DD-49D8-A188-1C88A6AC3F29Q37322280-082A7672-8301-42BB-8C84-89C6FBAF5C08Q38449501-26827FA0-8BE3-43AE-BB76-CAA35E336A4EQ40438301-10841DAB-58AB-4169-9C9C-BC50552F90FDQ40687265-167F8393-93C2-457C-AA63-47D15B53C5B8Q43406455-A62EFE0C-48F4-4A5F-86DC-099D6DCE59AE
P2860
Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Serologic responses in patient ...... lic and private specificities.
@ast
Serologic responses in patient ...... lic and private specificities.
@en
type
label
Serologic responses in patient ...... lic and private specificities.
@ast
Serologic responses in patient ...... lic and private specificities.
@en
prefLabel
Serologic responses in patient ...... lic and private specificities.
@ast
Serologic responses in patient ...... lic and private specificities.
@en
P2093
P2860
P356
P1476
Serologic responses in patient ...... lic and private specificities.
@en
P2093
P2860
P304
P356
10.1165/AJRCMB.22.5.3930
P577
2000-05-01T00:00:00Z